MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) today announced a cross license agreement with Eli Lilly and Company on the use of certain recombinant protein technologies. This agreement is part of a settlement to resolve patent litigation initiated by Applied Molecular Evolution (AME), a wholly owned subsidiary of Lilly, involving several U.S. patents of the Kauffman patent family. The settlement agreement covers MorphoSys’ and its partners’ past, present and future use and commercialisation of all versions of its HuCAL® libraries, as well as its TRIM technology. Under the agreement, MorphoSys receives a license under the Kauffman patent estate to generate and screen certain recombinant peptide and protein libraries and to commercialize any resulting products. Financial terms were not disclosed. The agreement also provides Lilly access to the MorphoSys HuCAL GOLD® technology for Lilly's internal research & development programs. For any therapeutic antibodies Lilly develops under the agreement, it will pay MorphoSys exclusive licensing fees, success fees, milestone payments and royalties on end products.